本帖最后由 老马 于 2013-3-13 13:43 编辑 ' a! a! M$ r6 O' t' k$ U+ n. f
% w. i. |# u4 d. q$ d健择（吉西他滨）+顺铂+阿瓦斯汀
0 \4 `* A7 m5 x Gemzar +Cisplatin + Avastin+ ]% Z* F+ l3 ~4 f
http://annonc.oxfordjournals.org/content/21/9/1804.full9 t( d9 F- `! ^# ?. E# v0 X/ x
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ' ]! j: v+ a4 {2 F) u7 J
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 i* C4 `( o2 ] X+ O3 uResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. * S0 R! B) ~, D8 W1 v: k
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 945)
% a1 h7 y- R, j/ M; K
华为网盘附件：
1 \$ c0 J% S3 W2 f【华为网盘】ava.JPG
?: e! Q! M. J# F! f% a |
显身卡
